No, you should not switch from tofacitinib to leflunomide in a patient with controlled disease activity
For a patient with rheumatoid arthritis who is currently tolerating tofacitinib with controlled disease activity, continuing tofacitinib is strongly recommended over switching to leflunomide. There is no clinical rationale to switch from a more advanced therapy that is working well to a less potent conventional synthetic DMARD.
Treatment Hierarchy and Positioning
The current treatment paradigm clearly positions these medications at different levels of the therapeutic ladder:
Leflunomide is a first-line conventional synthetic DMARD (csDMARD), recommended when methotrexate is contraindicated or not tolerated 1, 2, 1, 2. It serves as an alternative initial therapy alongside methotrexate and sulfasalazine 3.
Tofacitinib is a targeted synthetic DMARD (tsDMARD) positioned for use after inadequate response to csDMARDs or biologics 1. The 2014 EULAR guidelines specifically state: "Tofacitinib may be considered after biological treatment has failed" 1. The 2019 update places JAK inhibitors like tofacitinib alongside biologics as second-line options when csDMARDs fail 2.
Why Switching Would Be Inappropriate
1. Therapeutic Regression
Moving from tofacitinib to leflunomide represents stepping backward in the treatment algorithm. This violates the fundamental principle of maintaining disease control once achieved. The 2021 ACR guidelines emphasize continuing effective therapy rather than de-escalating when disease is controlled 3.
2. Efficacy Differences
While leflunomide shows comparable efficacy to methotrexate in head-to-head trials 4, 5, tofacitinib has demonstrated superior efficacy in patients who have failed csDMARDs 6. Real-world data shows tofacitinib achieves 63.6% low disease activity and 31.6% remission rates at 6 months 7.
3. Risk of Disease Flare
Switching from a working therapy to a less potent one carries substantial risk of disease reactivation. The guidelines consistently warn that stopping or reducing effective DMARDs often leads to flares 8, 9.
When Tofacitinib Should Be Reconsidered
The only scenarios where switching FROM tofacitinib might be appropriate are:
- Safety concerns: Development of serious adverse events, particularly in patients with cardiovascular risk factors, history of malignancy, or thromboembolic risk 9
- Specific infections: Recurrent herpes zoster infections (incidence 0.9-12.9% in real-world data) 10, 11
- Treatment failure: Loss of efficacy despite adequate dosing
- Patient preference: Strong preference for different route of administration or concern about long-term safety
In these cases, switching to a biologic DMARD (not leflunomide) would be more appropriate 1, 2.
The Correct Approach
For your patient with controlled disease on tofacitinib:
Continue current therapy - The 2021 ACR guidelines conditionally recommend continuing TNF inhibitors, non-TNF biologics, or tofacitinib rather than discontinuing when disease activity is low 8
Monitor appropriately - Assess disease activity every 3-6 months when stable 2
Consider tapering only if in sustained remission - The 2019 EULAR recommendations suggest cautious dose reduction may be considered only after sustained long-term remission 2, but this means reducing tofacitinib dose, not switching to leflunomide
Address safety monitoring - Ensure appropriate screening for cardiovascular risk, malignancy history, and infection risk given the 2022 safety updates regarding JAK inhibitors 9
Common Pitfall to Avoid
Do not confuse "treatment sequencing" with "treatment substitution." Leflunomide is appropriate as an alternative to methotrexate in treatment-naive patients or as part of initial csDMARD strategies 1, 2, 3. It is NOT an appropriate substitute for a working tsDMARD or biologic in a patient with controlled disease.